In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...
In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...
September S&P 500 E-Mini futures (ESU24) are up +0.04%, and September Nasdaq 100 E-Mini futures (NQU24) are down -0.11% this morning as market participants looked ahead to comments from Federal Reserve...
The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...
These stocks might not be small for too much longer.
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP